Xtalks — The Life Science Community™, Online webinar
2026-10-29
From Robust Clone Outgrowth to GMP-Ready Cell Banks Ensuring the clinical reliability of iPSC-derived products begins with genetically stable and well-characterized starting materials. This webinar presents a multilayer strategy designed to safeguard the genomic integrity of iPSCs and examines a Master Cell Bank manufacturing process based on single-cell cloning. By integrating the VIPS™ platform for image-verified single-cell cloning and seeding together with CellMetric for automated clonal outgrowth imaging, the workflow supports traceable, high-confidence clone selection, an essential foundation for GMP-ready Master Cell Banks and downstream clinical manufacturing. This approach enables the identification and expansion of genetically intact clones, strengthening the overall safety profile, ensuring consistent batch manufacturing and supporting the clinical robustness of iPSC-based therapies. The featured panelists will discuss a workflow-centric approach to optimizing single-cell cloning for iPSC programs, spanning early clone establishment, culture condition selection and the transition toward GMP-ready Master and Working Cell Banks. Drawing on real-world development experience, the session will explore how media and matrix choices influence clonal performance, how cellular stress contributes to clonal drift and genetic instability and how upstream workflow design can mitigate these risks without relying on project-specific datasets. The discussion will also highlight where single-cell recloning (“clonal reset”) and staged genetic integrity monitoring can be integrated into broader upstream strategies to support consistent, scalable and regulatory ready iPSC manufacturing. Attendees will gain practical insight into building robust single-cell cloning workflows, supported by image-verified technologies, that balance scientific rigor with real-world development constraints. Register for this webinar to learn how iPSC manufacturing workflows can support genetically stable clones, GMP-ready cell banks and consistent clinical manufacturing.
|